Notifications
- 2024.12.17Luxna and SPI Announce License Agreement for manufacturing and sales of Luxna’s xeno modified nucleic acid amidite
- 2024.11.06Inocras and Summit Pharmaceuticals International Corporation Announce Collaboration aim to Transform Clinical Genomics in Japan
- 2024.10.15Summit Pharmaceuticals International Corporation Invests in EVerMed Inc.
- 2024.06.26Summit Pharmaceuticals International Corporation Statement for UK Modern Slavery Act 2015 (FY 2023 Statement)
- 2024.06.05SPI Earns Silver Medal in EcoVadis Sustainability Assessment
- 2024.01.23Signing of the United Nations Global Compact
- 2023.12.13Signed an Exclusive Distributorship Agreement with Texcell
- 2023.07.31Summit Pharmaceuticals International Corporation Statement for UK Modern Slavery Act 2015 (FY 2022 Statement)
- 2023.06.02Signing of Exclusive Distributorship Agreement with EVERZOM
- 2022.06.30Summit Pharmaceuticals International Corporation Statement for UK Modern Slavery Act 2015 (FY 2021 Statement)
- 2022.04.14Fukushima Medical University aim to accelerate cancer research by contributing their patient derived organoids to the CancerTools.org initiative
- 2021.10.05Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2020 Statement)